EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Aerosol Characteristics of Nebulized Tranexamic Acid 100 mg/mL for Hemoptysis Treatment—Proof-of-Concept Study

Gerrit Seifert, Frank Erdnüß, Wolfgang Kamin, Irene Krämer

Journal of Pharmaceutical and BioTech Industry · 2025

DOI: 10.3390/jpbi2030012 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Pharmaceutical and BioTech Industry, 2025. Verfasst von Gerrit Seifert und 3 weiteren Autor:innen. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Off-label nebulization of tranexamic acid (TXA) solution is common practice for the treatment of hemoptysis. However, data regarding nebulization protocols, resulting aerodynamic parameters of the generated aerosol, and corresponding biopharmaceutical parameters are missing. The aim of this in vitro study was to investigate the aerosol characteristics of nebulized sterile, aqueous TXA solution.

Methods

TXA solution 100 mg/mL was nebulized for 2 min by a multi-dose vibrating mesh nebulizer using 15 L/min and 30 L/min air flow rates. The generated aerosol was analyzed by a Next Generation Cascade Impactor. For each air flow rate, the mean Fine Particle Dose (FPD), Fine Particle Fraction (FPF), the Mass Median Aerodynamic Diameter (MMAD), and Geometric Standard Deviation (GSD) were quantified.

Results

Nebulization at 15 L/min air flow rate resulted in a MMAD of 6.68 ± 0.23 µm and GSD of 2.02 ± 0.16. The FPD < 5 µm was 16.56 ± 0.45 mg, the FPF < 5 µm 28.91 ± 3.40%. Nebulization at 30 L/min air flow rate revealed a MMAD of 5.18 ± 0.12 µm and GSD of 2.14 ± 0.10. The FPD < 5 µm was 16.30 ± 1.38 mg, the FPF < 5 µm 35.43 ± 0.59%.

Conclusions

Nebulization of TXA 100 mg/mL solution by a specified vibrating mesh nebulizer generated an aerosol particle distribution and deposition pattern suitable for the treatment of hemoptysis with bronchial origin.

Zitieren

APA

Seifert, G., Erdnüß, F., Kamin, W., & Krämer, I. (2025). Aerosol Characteristics of Nebulized Tranexamic Acid 100 mg/mL for Hemoptysis Treatment—Proof-of-Concept Study. Journal of Pharmaceutical and BioTech Industry. https://doi.org/10.3390/jpbi2030012

Vancouver

Seifert G, Erdnüß F, Kamin W, Krämer I. Aerosol Characteristics of Nebulized Tranexamic Acid 100 mg/mL for Hemoptysis Treatment—Proof-of-Concept Study. Journal of Pharmaceutical and BioTech Industry. 2025. doi:10.3390/jpbi2030012

BibTeX
@article{Seifert2025,
  author = {Seifert, Gerrit and Erdnüß, Frank and Kamin, Wolfgang and Krämer, Irene},
  title = {Aerosol Characteristics of Nebulized Tranexamic Acid 100 mg/mL for Hemoptysis Treatment—Proof-of-Concept Study},
  journal = {Journal of Pharmaceutical and BioTech Industry},
  year = {2025},
  doi = {10.3390/jpbi2030012}
}
Kostenlos starten →